R406

For research use only. Not for use in humans.

目录号：S2194

CAS No. 841290-81-1

R406 是一种有效的 Syk 抑制剂，无细胞试验中IC50为41 nM，对Syk抑制作用强，但是不抑制Lyn，对Flt3的作用比对Syk低5倍。R406 可诱导凋亡。Phase 1。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 2341.19	现货
5mg	RMB 1421.87	现货
10mg	RMB 2207.88	现货
50mg	RMB 7119.85	现货
200mg	RMB 16298.1	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的R406发表文献64篇：

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Cancer Cell, 2017, 31(4):549-562

PubMed: 28399410 ( click the link to review the publication )

Nat Med, 2016, 22(8):915-23

PubMed: 27428901 ( click the link to review the publication )

Cell Rep, 2021, 34(11):108870

PubMed: 33730585 ( click the link to review the publication )

J Leukoc Biol, 2021, 10.1002/JLB.2A0520-334R

PubMed: 33884657 ( click the link to review the publication )

J Biol Chem, 2021, S0021-9258(21)00238-6

PubMed: 33639170 ( click the link to review the publication )

Cell Death Dis, 2020, 11(11):956

PubMed: 33159047 ( click the link to review the publication )

Front Immunol, 2020, 11:610523

PubMed: 33552071 ( click the link to review the publication )

Aging (Albany NY), 2020, 7;12(9):8221-8240

PubMed: 32379705 ( click the link to review the publication )

Biomolecules, 2020, 10(9)E1283

PubMed: 32899943 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(19)E7009

PubMed: 32977621 ( click the link to review the publication )

ScholarsArchive@OSU, 2020, 51

PubMed: N/A ( click the link to review the publication )

Nat Cell Biol, 2019, 21(2):203-213

PubMed: 30664786 ( click the link to review the publication )

mBio, 2019, 10(3)e00574-19

PubMed: 31064828 ( click the link to review the publication )

PLoS Pathog, 2019, 15(8):e1007923

PubMed: 31449558 ( click the link to review the publication )

Cell Death Dis, 2019, 10(8):555

PubMed: 31324751 ( click the link to review the publication )

Front Immunol, 2019, 10:921

PubMed: 31139177 ( click the link to review the publication )

J Immunol, 2019, 203(12):3225-3236

PubMed: 31704879 ( click the link to review the publication )

Molecules, 2019, 24(20)E3640

PubMed: 31600968 ( click the link to review the publication )

PLoS One, 2019, 14(1):e0210879

PubMed: 30668583 ( click the link to review the publication )

Mucosal Immunol, 2019, 12(2):425-433

PubMed: 30664707 ( click the link to review the publication )

J Control Release, 2018, 288:227-238

PubMed: 30219279 ( click the link to review the publication )

J Bone Miner Res, 2018, 33(1):167-181

PubMed: 28914985 ( click the link to review the publication )

Front Immunol, 2018, 9:37

PubMed: 29410669 ( click the link to review the publication )
J Mol Cell Cardiol, 2018, 115:82-93

PubMed: 29274344 ( click the link to review the publication )

Cell Microbiol, 2018, 20(2)

PubMed: 29125705 ( click the link to review the publication )

Chem Res Toxicol, 2018, 31(2):127-136

PubMed: 29156121 ( click the link to review the publication )

Leukemia, 2017, 31(8):1686-1694

PubMed: 27890932 ( click the link to review the publication )

Cancer Res, 2017, 77(8):1818-1830

PubMed: 28130226 ( click the link to review the publication )

EMBO Rep, 2017, 18(9):1604-1617

PubMed: 28705801 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2586-2597

PubMed: 28835384 ( click the link to review the publication )

J Immunol, 2017, 198(8):3181-3194

PubMed: 28264968 ( click the link to review the publication )

PLoS Comput Biol, 2017, 13(3):e1005432

PubMed: 28306714 ( click the link to review the publication )

Oncotarget, 2017, 8(7):10931-10944

PubMed: 28077790 ( click the link to review the publication )

Clin Immunol, 2017, 175:69-74

PubMed: 27919819 ( click the link to review the publication )

Blood, 2017, 129(6):759-770

PubMed: 28011673 ( click the link to review the publication )

Blood, 2016, 127(25):3192-201

PubMed: 27095788 ( click the link to review the publication )

Leukemia, 2016, 30(5):1116-25

PubMed: 26867669 ( click the link to review the publication )

Cancer Res, 2016, 76(23):6937-6949

PubMed: 27758892 ( click the link to review the publication )

J Invest Dermatol, 2016, 136(1):192-201

PubMed: 26763439 ( click the link to review the publication )

PLoS Pathog, 2016, 12(3):e1005487

PubMed: 26943817 ( click the link to review the publication )

PLoS Genet, 2016, 12(9):e1006279

PubMed: 27588951 ( click the link to review the publication )

PLoS One, 2016, 11(10):e0164895

PubMed: 27768734 ( click the link to review the publication )

J Allergy Clin Immunol, 2016, 138(3):839-851

PubMed: 27056269 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(1):57-67

PubMed: 25487280 ( click the link to review the publication )

Blood, 2015, 126(16):1911-20

PubMed: 26272216 ( click the link to review the publication )

Leukemia, 2015, 29(6):1350-9

PubMed: 25482129 ( click the link to review the publication )

Mol Syst Biol, 2015, 11(1):789

PubMed: 25699542 ( click the link to review the publication )
J Leukoc Biol, 2015, 10.1189/jlb.3HI0814-371RR

PubMed: 25605870 ( click the link to review the publication )

J Biomol Screen, 2015, 10.1177/1087057115585724

PubMed: 25948491 ( click the link to review the publication )

Immunity, 2014, 40(3):389-99

PubMed: 24631154 ( click the link to review the publication )

Blood, 2014, 124(4):590-7

PubMed: 24948657 ( click the link to review the publication )

J Clin Invest, 2014, 124(11):5074-84

PubMed: 25329694 ( click the link to review the publication )

Nat Commun, 2014, 5:5444

PubMed: 25392121 ( click the link to review the publication )

J Bone Miner Res, 2014, 29(12):2618-35

PubMed: 24916406 ( click the link to review the publication )

Eur J Med Chem, 2014, 86C:664-675

PubMed: 25222877 ( click the link to review the publication )

Eur J Immunol, 2014, 44(12):3729-40

PubMed: 25251945 ( click the link to review the publication )

Exp Cell Res, 2014, 322(1):99-107

PubMed: 24406398 ( click the link to review the publication )

PLoS One, 2014, 9(5):e96703

PubMed: 24846290 ( click the link to review the publication )

Exp Dermatol, 2014, 23(12):884-9

PubMed: 25267545 ( click the link to review the publication )

Blood, 2013, 122(4):580-9

PubMed: 23699602 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(3):586-97

PubMed: 23231952 ( click the link to review the publication )

Br J Haematol, 2013, 163(5):590-602

PubMed: 24117128 ( click the link to review the publication )

UVIC, 2013, Meritxell Aguiló García

PubMed: ( click the link to review the publication )

产品安全说明书

Syk抑制剂选择性比较

生物活性

产品描述

R406 是一种有效的 Syk 抑制剂，无细胞试验中IC50为41 nM，对Syk抑制作用强，但是不抑制Lyn，对Flt3的作用比对Syk低5倍。R406 可诱导凋亡。Phase 1。

特性

Rigel选择R406作为治疗风湿性关节炎的潜在领先药物。

靶点

Flt3 ^[1] (Cell-free assay)	Syk ^[1] (Cell-free assay)
	41 nM

体外研究

R406强抑制免疫球蛋白 E (IgE)和 IgG调节的受体信号活性。R406抑制IgE抗体诱导的 LTC4 ，细胞因子和趋化因子的产生和释放, 包括TNFα, IL-8, 和GM-CSF。R406 抑制肥大细胞中T细胞Syk底物链接蛋白的激活和B细胞中B细胞链接蛋白/SLP65的磷酸化作用。R406 结合到Syk的ATP结合袋中，抑制Syk的激酶活性， R406是ATP竞争性抑制剂，K_i为30 nM。R406阻断单核细胞/巨噬细胞和中性白细胞中Syk依赖的FcR调节活性，且阻断B淋巴细胞中BCR调节活性。^[1]406 明显诱导慢性淋巴细胞白血病（CCL）细胞凋亡，且阻断CCL3和CCL4 分泌。^[2] R406有效抑制血小板信号，且抑制使用特殊抗体或 HIT 病患的血浆通过FcγRIIA 交叉结合形成的功能。^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
AMO-1	NISw[ZFHfW6ldHnvckBCe3OjeR?=	MWOxJO69VQ>?	MoHEN:KhcA>?		NIXE[YRz\WS3Y3XzJI1q\3KjdHnvcuKh	MnrEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{NUG3OlEoRjJ4MkWxO\|YyRC:jPh?=
U266	NFnWb2ZHfW6ldHnvckBCe3OjeR?=	M4qwWFEh\|ryP	NH\hT4I{yqCq		M3:1Z5Jm\HWlZYOgcYloemG2aX;uxsA>	M{T5SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkWxO\|YyLz5{NkK1NVc3OTxxYU6=
Jeko-1	NULFRVkyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NITVd3c1QCCq		MlnDTWM2OD13LkC2PFI3KM7:TR?=	NUTsZ4hDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N\|U4PTVpPkK1PFM2PzV3PD;hQi=>
Mino	NXu2Z4JQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M121UVQ5KGh?		NGPrXFhKSzVyPUWuO\|A5PTRizszN	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh\|NUe1OUc,OjV6M{W3OVU9N2F-
Jeko-1	MUTBdI9xfG:\|aYOgRZN{[Xl?	MV61xsDPxE1?	MoLSNlQhcA>?		NHHoZ\|hqdmS3Y3XzJFI2NjIEoNMxxsA{NjMEoDWgZZBweHSxc3nz	NInhbJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUizOVc2PSd-MkW4N\|U4PTV:L3G+
primary MCL	NFe3e\|ZCeG:ydH;zbZMhSXO\|YYm=	NFvZWWYzKML3TR?=	NEfaNlEzPCCq		NEjISpdqdmO{ZXHz[ZMhe2mpbnnmbYNidnSueTDhdI9xfG:\|aYRCpC=>	Mli3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|OEizO\|MoRjJ3M{i4N\|c{RC:jPh?=
PBMCs	MWPD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	Mn3WNE02OCEQvF2=	MljaNlQhcA>?	MWnEUXNQ	NFfWUnhqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7	NF6xOow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGyO\|g3Oid-MkWxNlc5PjJ:L3G+
PBMCs	NXOweGliTnWwY4Tpc44hSXO\|YYm=	NF;0XpQ2KM7:TR?=	NVHFeWZvOSCq	NFHseWpFVVOR	NVHLe\|Zn\GWlcnXhd4V{KHSqZTDj[YxtKG2rZ4LheIlwdg>?	NGr5Z4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGyO\|g3Oid-MkWxNlc5PjJ:L3G+
CFSE-CD4+ T	MoP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVrTU5llOC5yNkK1MVEh\|ryP	NHrGUYg1KGR?		MnPnZoxw[2u\|IIDyc4xq\mW{YYTpc44hd2ZiR2\ISE1l\XKrdnXkJGNFPCwEoGSgZ4VtdHNiYX7kJGNFOTGkK9MgZ4VtdHN?	NGHUXnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[3PVk5Oid-MkS2O\|k6QDJ:L3G+
CFSE-CD11b+	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFH0W3IxNjB4MkWtNUDPxE1?	MX[4JIQ>		NX20dG1y[myxY3vzJJBzd2yrZnXyZZRqd25ib3[gS3ZJTC2mZYLpeoVlKEOGNDxCpHQh[2WubIOgZY5lKEOGMUHiL:Kh[2WubIO=	NX3GRmtpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2O\|k6QDJpPkK0Olc6QTh{PD;hQi=>
HMECs	NGq0bFdHfW6ldHnvckBCe3OjeR?=	MnO5NE0yOCEQvF2=	NInTSYYzOCCvaX6=		M3vDPYlvcGmkaYTzJHZGT0Zvc4TpcZVt[XSnZDDy[Yxm[XOnIH;mJG5Q	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN{OUW0OEc,OjR\|Mkm1OFQ9N2F-
AB5	NUG0dY04SXCxcITvd4l{KEG\|c3H5	NX[5PJAyOC1{LkWg{txO	MXW0PEBp	NYDDb2ZNTE2VTx?=	M{mzS4lv\HWlZYOgZZBweHSxc3nz	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN7OEmxNUc,OjN\|OUi5NVE9N2F-
JB7	M1rDO2Fxd3C2b4Ppd{BCe3OjeR?=	MWqwMVIvPSEQvF2=	MXW0PEBp	M2roRmROW09?	NInKOFBqdmS3Y3XzJIFxd3C2b4Ppdy=>	NWi2T3B4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzPVg6OTFpPkKzN\|k5QTFzPD;hQi=>
AB5	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3fnRVAuOi53IN88US=>	M4jpTlQ5KGh?	MoXOSG1UVw>?	MXPpcoR2[2W\|IHPlcIwh[3mlbHWgZZJz\XO2	NH;qe4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O5PFkyOSd-MkOzPVg6OTF:L3G+
JB7	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnj4NE0zNjVizszN	MXe0PEBp	NWfVbXVKTE2VTx?=	NIixeYhqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0	M2DKOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{m4PVEyLz5{M{O5PFkyOTxxYU6=
RL	NILRO5ZHfW6ldHnvckBCe3OjeR?=	MVeyMlUwPSEQvF2=	MV[yOE81QCCq	MVPEUXNQ	MWPpcoR2[2W\|IHGgdI91\W62IHTlZ5Jm[XOnIHnuJG1OWC17IH3SUmEh\XiycnXzd4lwdg>?	NXX2dnY3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5NlY6PjVpPkKxPVI3QTZ3PD;hQi=>
RL	NUn3WYJtTnWwY4Tpc44hSXO\|YYm=	MonZNU8zNjVizszN	NWn4c2VjOjRiaB?=	M4P4XGROW09?	M2L1[pJm\HWlZYOgeIhmKGGldHn2ZZRqd25ib3[gRYt1KGGwZDDwO\|BUPkt?	MmnVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7Mk[5OlUoRjJzOUK2PVY2RC:jPh?=
platelet	NHHwT2tHfW6ldHnvckBCe3OjeR?=	MlT2NeKh\|ryv	MUm1JI1qdg>?		Mn\PbY5pcWKrdIOgSoPPu1KLSVGtcYVlcWG2ZXSgdIxifGWuZYSgZYdoemWpYYTpc44>	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTh2OE[5OEc,OjF6NEi2PVQ9N2F-
platelet	NFnRPHJHfW6ldHnvckBCe3OjeR?=	M{exclAvODVxMT:yMlUh\|ryP	MkfHOUBucW5?		MoT1bY5pcWKrdIOgeIhmKHOrZ37hcIlv\yCvZXPoZY5qe22\|IHTve45{fHKnYX2gc4YhTmQQs2LJTWE>	NUDXSoZmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4OFg3QTRpPkKxPFQ5Pjl2PD;hQi=>
DoHH2	M4GxZ2Fxd3C2b4Ppd{BCe3OjeR?=	M2TEcVAwOy9zMDFOwG0>	NI[5W3I1QCCq		NF3IOllqdmS3Y3XzJINmdGxiZHXheIghe2mpbnnmbYNidnSueR?=	NYjCUnB1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC4O\|U1ODhpPkKwPFc2PDB6PD;hQi=>
Jeko-1	NIS2c4RCeG:ydH;zbZMhSXO\|YYm=	MnKzNE8{NzFyIN88US=>	MYW0PEBp		M4nDZolv\HWlZYOgZ4VtdCCmZXH0bEB{cWewaX\pZ4FvfGy7	NVvsZXR6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC4O\|U1ODhpPkKwPFc2PDB6PD;hQi=>
Raji	NUKxeJR6SXCxcITvd4l{KEG\|c3H5	NVTrVId1OC9\|L{GwJO69VQ>?	MV60PEBp		M{LiO4lv\HWlZYOgZ4VtdCCmZXH0bEB{cWewaX\pZ4FvfGy7	NHLkelk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEi3OVQxQCd-MkC4O\|U1ODh:L3G+
DHL4	NGLRXmhCeG:ydH;zbZMhSXO\|YYm=	M1y3[FAwOS92IN88US=>	MVm5OkBp		NH;uPI9qdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5	NVHVVIRQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiwNFY3QTZpPkG4NFA3Pjl4PD;hQi=>
LY7	NYLYZmdxSXCxcITvd4l{KEG\|c3H5	MlLpNE8yNzRizszN	Mnq4PVYhcA>?		MVjpcoR2[2W\|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7	MoHSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOThyME[2PVYoRjF6MEC2Olk3RC:jPh?=
LY3	NXO0d5N5SXCxcITvd4l{KEG\|c3H5	MmixNE8yNzRizszN	MmWwPVYhcA>?		NFzTdlZqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5	NVG3ZW1lRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiwNFY3QTZpPkG4NFA3Pjl4PD;hQi=>
DHL6	MlnTRZBweHSxc3nzJGF{e2G7	M2LLVlAwOS92IN88US=>	M1XNdlk3KGh?		NHTT[4ZqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5	MnHnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOThyME[2PVYoRjF6MEC2Olk3RC:jPh?=
LY10	NWj4fWZoSXCxcITvd4l{KEG\|c3H5	MVOwM\|EwPCEQvF2=	NH7mOG46PiCq		MlTTbY5lfWOnczDhdI9xfG:\|aYOg[I9{\SCmZYDlcoRmdnSueR?=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDByNk[5Okc,OThyME[2PVY9N2F-
DHL10	M1H3NWFxd3C2b4Ppd{BCe3OjeR?=	NELl[5gxNzFxNDFOwG0>	MVe5OkBp		NET6b5ZqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5	Mmr5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOThyME[2PVYoRjF6MEC2Olk3RC:jPh?=
Wsu-NHL	Mn7URZBweHSxc3nzJGF{e2G7	NWPwTmlvOC9zL{Sg{txO	MmPVPVYhcA>?		NWPheWFDcW6mdXPld{BieG:ydH;zbZMh\G:\|ZTDk[ZBmdmSnboTsfS=>	NHryNGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOECwOlY6Pid-MUiwNFY3QTZ:L3G+
LY18	M4fRbGFxd3C2b4Ppd{BCe3OjeR?=	M1X5fFAwOS92IN88US=>	M2XGb\|k3KGh?		MXvpcoR2[2W\|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7	MorEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOThyME[2PVYoRjF6MEC2Olk3RC:jPh?=
LY1	NXzvRXRKSXCxcITvd4l{KEG\|c3H5	NXrFVFl2OC9zL{Sg{txO	MlTMPVYhcA>?		MULpcoR2[2W\|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7	NUDzT5U6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiwNFY3QTZpPkG4NFA3Pjl4PD;hQi=>
DHL8	NFKyWYtCeG:ydH;zbZMhSXO\|YYm=	M4n6R\|AwOS92IN88US=>	MorLPVYhcA>?		M2HyZYlv\HWlZYOgZZBweHSxc3nzJIRwe2ViZHXw[Y5l\W62bIm=	NEX4cpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOECwOlY6Pid-MUiwNFY3QTZ:L3G+
DHL4	MWDBdI9xfG:\|aYOgRZN{[Xl?	M4X5[lQh\|ryP	NV7JWmE6QTZiaB?=		M4DQd4lv\HWlZYOgZ4xm[X[jZ3Wgc4Yh[2G\|cHHz[ZMhQSCjbnSgN{wh[nW2IH7veEBk[XOyYYPlJFg>	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDByNk[5Okc,OThyME[2PVY9N2F-
DHL6	M1zoT2Fxd3C2b4Ppd{BCe3OjeR?=	MX20JO69VQ>?	MUi5OkBp		M1K3TIlv\HWlZYOgZ4xm[X[jZ3Wgc4Yh[2G\|cHHz[ZMhQSCjbnSgN{wh[nW2IH7veEBk[XOyYYPlJFg>	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDByNk[5Okc,OThyME[2PVY9N2F-
LY3	NXHqTHNGSXCxcITvd4l{KEG\|c3H5	M2TKS\|Qh\|ryP	M1vMZ\|k3KGh?		MVjpcoR2[2W\|IHPs[YF3[WenIH;mJINie3Cjc3XzJFkh[W6mIEOsJIJ2fCCwb4SgZ4F{eGG\|ZTC4	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDByNk[5Okc,OThyME[2PVY9N2F-
LY7	M{C3NGFxd3C2b4Ppd{BCe3OjeR?=	MnrzOEDPxE1?	Mlq1PVYhcA>?		MlHUbY5lfWOnczDjcIVifmGpZTDv[kBk[XOyYYPld{A6KGGwZDCzMEBjfXRibn;0JINie3Cjc3WgPC=>	M{nCd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MEC2Olk3Lz5zOECwOlY6PjxxYU6=
DHL4	MmeySpVv[3Srb36gRZN{[Xl?	NF7oRm41KM7:TR?=	NWC5c2lVOTZiaB?=		MVvpcohq[mm2czD0c45q[yCETF7LJJR6em:\|aX7lJJBpd3OyaH;yfYxifGmxbh?=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDByNk[5Okc,OThyME[2PVY9N2F-
LY7	NYDkfYZyTnWwY4Tpc44hSXO\|YYm=	MWe0JO69VQ>?	MnTvNVYhcA>?		MXHpcohq[mm2czD0c45q[yCETF7LJJR6em:\|aX7lJJBpd3OyaH;yfYxifGmxbh?=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDByNk[5Okc,OThyME[2PVY9N2F-
LY3	Mnr1SpVv[3Srb36gRZN{[Xl?	NIH1eGM1KM7:TR?=	MUKxOkBp		Mmn5bY5pcWKrdIOgeI9vcWNiQlzOT{B1gXKxc3nu[UBxcG:\|cHjvdplt[XSrb36=	NE\ye5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOECwOlY6Pid-MUiwNFY3QTZ:L3G+
DHL6	MmDWSpVv[3Srb36gRZN{[Xl?	M13MVFQh\|ryP	M{POcVE3KGh?		NYL0c3kycW6qaXLpeJMhfG:waXOgRmxPUyC2eYLvd4lv\SCyaH;zdIhwenmuYYTpc44>	MlroQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOThyME[2PVYoRjF6MEC2Olk3RC:jPh?=
LY10	M3K1emZ2dmO2aX;uJGF{e2G7	MVO0JO69VQ>?	NUjMWYpvOTZiaB?=		MkKxbY5pcWKrdIOgeI9vcWNiQlzOT{B1gXKxc3nu[UBxcG:\|cHjvdplt[XSrb36=	NV3qe3QzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiwNFY3QTZpPkG4NFA3Pjl4PD;hQi=>
Wsu-NHL	NHX2ZldHfW6ldHnvckBCe3OjeR?=	MkDIOEDPxE1?	MUmxOkBp		NFPMe2lqdmirYnn0d{B1d26rYzDCUG5MKHS7cn;zbY5mKHCqb4PwbI9zgWyjdHnvci=>	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDByNk[5Okc,OThyME[2PVY9N2F-
LY18	M2XDPGZ2dmO2aX;uJGF{e2G7	MVS0JO69VQ>?	NGrHUYUyPiCq		M37NfYlvcGmkaYTzJJRwdmmlIFLMUmshfHm{b4PpcoUheGixc4Doc5J6dGG2aX;u	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDByNk[5Okc,OThyME[2PVY9N2F-
MV411	NV[5N213TnWwY4Tpc44h[XO\|YYm=		M4fjVFczKGi{cx?=		NVKxcmxrUW6qaXLpeIlwdiCxZjDGcJQ{KGmwIHj1cYFvKE2YNEGxJINmdGy\|IHHzd4V{e2WmIHHzJIF{e2W\|c3XkJIF{KHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGmwY4XiZZRqd25iYomgd5Bm[3S{b4Doc5RwdWW2comsJGVEPTB;MD6wNe69VS5?	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd5OUWxOEc,OjR5N{m1NVQ9N2F-
TF1	MnTZSpVv[3Srb36gZZN{[Xl?		MXqxJIhz		MmjOTY5pcWKrdHnvckBw\iCMYXuyJIlvKGW{eYTodo9xd2mndHnuMZN1cW23bHH0[YQhcHWvYX6gWGYyKGOnbHzzJIF{e2W\|c3XkJIF{KGG\|c3Xzd4VlKGG\|IIDoc5NxcG9vU4TheFUh[W[2ZYKgNUBpeiCrbnP1ZoF1cW:wLDDFR\|UxRTBwMEGz{txONg>?	NV61VI1JRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3O\|k2OTRpPkK0O\|c6PTF2PD;hQi=>
neutrophils	MUDGeY5kfGmxbjDhd5NigQ>?				NVnMeJhSUW6qaXLpeIlwdiCxZjDTXWshcW5iaIXtZY4hdmW3dILvdIhqdHNiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGZk\XC\|aXzvcnIyN0[lZ3HtcYFTNW2nZHnheIVlKHOrZ37hcIlv\yC{ZYPwc45{\XNuIFXDOVA:OC5yM{ROwG0v	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ3N{KxN{c,OjJ{NUeyNVM9N2F-
SK-M-MC	NF\FNoRHfW6ldHnvckBie3OjeR?=		M2rSS\|EhcHJ?		NWO2O5lxUW6qaXLpeIlwdiCxZjDS[ZQhcW5iaIXtZY4hW0tvTT3NR{Bk\WyuczDhd5Nme3OnZDDhd{Bie3Onc4Pl[EBieyCyaH;zdIhwenmuYYTpc44h[W[2ZYKgNUBpeiCrbnP1ZoF1cW:wLDDFR\|UxRTBwMEO2{txONg>?	NHXE[JA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe3PVUyPCd-MkS3O\|k2OTR:L3G+
mast cells	MlnnSpVv[3Srb36gZZN{[Xl?		MVixJIhz		NXPISGNrUW6qaXLpeIlwdiCxZjDjT4l1KGmwIIP0[Y0h[2WubDDmZYN1d3Jvc4TpcZVt[XSnZDDic45mKG2jcoLve{Bl\XKrdnXkJI1wfXOnIH3hd5Qh[2WubIOgZZN{\XO\|ZXSgZZMheGixc4Doc5J6dGG2aX;uJIFnfGW{IEGgbJIhcW6ldXLheIlwdixiRVO1NF0xNjB2Nt88UU4>	NVHHWINGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3O\|k2OTRpPkK0O\|c6PTF2PD;hQi=>
B-cells	MojvSpVv[3Srb36gZZN{[Xl?				MnOxTY5pcWKrdHnvckBw\iCVWVugbY4hcHWvYX6gRk1k\WyuczDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hTmOncIPpcI9vWjFxRnPnZY1u[VJvbXXkbYF1\WRic3nncoFtcW6pIILld5BwdnOnczygSWM2OD1yLkC0PO69VS5?	MlrLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{NUeyNVMoRjJ{MkW3NlE{RC:jPh?=
Ramos	M4XBW2Z2dmO2aX;uJIF{e2G7				NV3sc4ZTUW6qaXLpeIlwdiCxZjDTfYshcW5iYX70bYh2dWGwIFnnUU1{fGmvdXzheIVlKGi3bXHuJHJidW:\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHTlZ5Jm[XOnIHnuJGJEWi2vZXTpZZRm\CCETF7LJJBpd3OyaH;yfYxifGmxbjDifUBk\WyudXzhdkBie3OjeTygSWM2OD1yLkC1N:69VS5?	NF3Fdpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe3PVUyPCd-MkS3O\|k2OTR:L3G+
mesangial cells	M{G1b2Z2dmO2aX;uJIF{e2G7				M2\mR2lvcGmkaYTpc44hd2ZiU2nLJIlvKGO3bIT1doVlKGi3bXHuJI1me2GwZ3nhcEBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iRnPldJNqdG:wUkGvSoNo[W2vYWKtcYVlcWG2ZXSgd4lodmGuaX7nJJJme3CxboPld{whTUN3ME2wMlA2Ps7:TT6=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ3N{KxN{c,OjJ{NUeyNVM9N2F-
SK-N-SH	MXnGeY5kfGmxbjDhd5NigQ>?				MofKTY5pcWKrdHnvckBw\iCUZYSgbY4hcHWvYX6gV2suVi2VSDDj[YxteyxiRVO1NF0xNjB6zszNMi=>	NIHlVlY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK1O\|IyOyd-MkKyOVczOTN:L3G+
mouse bone marrow cells	M4myT2Z2dmO2aX;uJIF{e2G7				MYDJcohq[mm2aX;uJI9nKEmOMzDk[ZBmdmSnboSgdJJwdGmoZYLheIlwdiCrbjDDOVcwSjF4IH3veZNmKGKxbnWgcYFzem:5IHPlcIx{KHW\|aX7nJHs{UF22aIntbYRqdmViYomgcIlyfWmmIIPjbY51cWyuYYTpc44h[2:3boTpcoctKEmFNUC9NE4yPDgQvF2u	NEnLSW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEeyOlgxPid-MkS3NlY5ODZ:L3G+
B-cells	MkTnSpVv[3Srb36gZZN{[Xl?		MUWxJIhz		NVnNeFQ5UW6qaXLpeIlwdiCxZjDTfYshcW5iYXzwbIFK\01vc4TpcZVt[XSnZDDoeY1idiCEIHPlcIx{KGG\|c3Xzd4VlKGG\|IHPlcIwheHKxbHnm[ZJifGmxbjDh[pRmeiBzIHjyJIlv[3WkYYTpc44h[nliZnzve{BkgXSxbXX0dpktKEWFNUC9NE4yPTIQvF2u	M3rsRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{e5OVE1Lz5{NEe3PVUyPDxxYU6=
THP1	M2rvPWZ2dmO2aX;uJIF{e2G7				M{fOUmlvcGmkaYTpc44hd2ZiU2nLJIlvKGi3bXHuJHRJWDFiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGZk\XC\|aXzvcnIyN0[lZ3HtcYFTNW2nZHnheIVlKHOrZ37hcIlv\yC{ZYPwc45{\XNuIFXDOVA:OC5zN{JOwG0v	NYjhe2xYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyOVczOTNpPkKyNlU4OjF\|PD;hQi=>
B-cells	MVHGeY5kfGmxbjDhd5NigQ>?		NFizfWYyKGi{		MkXwTY5pcWKrdHnvckBw\iCVeXugbY4h[WyyaHHJ[20ue3SrbYXsZZRm\CCqdX3hckBDKGOnbHzzJIF{e2W\|c3XkJIF{KEOGOE[g[ZhxemW\|c3nvckBi\nSncjCxJIhzKGmwY4XiZZRqd25iYomg[oxwfyCleYTvcYV1enluIFXDOVA:OC5\|M{ZOwG0v	NYOxXItTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3O\|k2OTRpPkK0O\|c6PTF2PD;hQi=>
Ramos	NYTWcndwTnWwY4Tpc44h[XO\|YYm=				MWfJcohq[mm2aX;uJI9nKFO7azDpckBidnSrIFnnUU1{fGmvdXzheIVlKGi3bXHuJHJidW:\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IFLMUmsheGixc4Doc5J6dGG2aX;uJIJ6KGOnbHz1cIFzKGG\|c3H5MEBKSzVyPUCuOFU4\|ryPLh?=	NHvLR4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEeyOlgxPid-MkS3NlY5ODZ:L3G+
Rec1	M4HTcWZ2dmO2aX;uJIF{e2G7	MoXYNk42KHWP	NW\yR\|A5PiCqcoO=		NEX2OoFKdmirYnn0bY9vKG:oIFLUT{BxcG:\|cHjvdplt[XSrb36gbY4hcHWvYX6gVoVkOSClZXzsd{BifCB{LkWgeW0hcW6ldXLheIVlKG[xcjC2JIhzeyCkeTDX[ZN1\XKwIHLsc5R1cW6pIH3leIhw\A>?	MkDtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{MkK4O\|coRjJ3MkKyPFc4RC:jPh?=
Rec1	M4nXXWZ2dmO2aX;uJIF{e2G7	M33oSVIvPSC3TR?=	NV\JXoo1PiCqcoO=		NWfDd\|VNUW6qaXLpeIlwdiCxZjDTfYsheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJHJm[zFiY3XscJMh[XRiMj61JJVOKGmwY4XiZZRm\CCob4KgOkBpenNiYomgW4V{fGW{bjDicI91fGmwZzDt[ZRpd2R?	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ{Mki3O{c,OjV{MkK4O\|c9N2F-
Rec1	MmPjSpVv[3Srb36gZZN{[Xl?	M2PMUVIvPSC3TR?=	MnH1OkBpenN?		MorYTY5pcWKrdHnvckBw\iCOeX6gdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIGLlZ\|Eh[2WubIOgZZQhOi53IIXNJIlv[3WkYYTl[EBnd3JiNjDodpMh[nliV3XzeIVzdiCkbH;0eIlv\yCvZYToc4Q>	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ{Mki3O{c,OjV{MkK4O\|c9N2F-
SJ-GBM2	NUnod4xyeUiWUzDhd5NigQ>?				M4DLNpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz	NV[4SYZVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673	NGXZcXNyUFSVIHHzd4F6				NUTkN4s2eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFG2O\|Mh[2WubIO=	NVX6SnFYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC	MVLxTHRUKGG\|c3H5				NGr6OllyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=>	NFy4Z4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB-EBc1	M3:zdpFJXFNiYYPzZZk>				NVvtUIl4eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CMWVD[zFiY3XscJM>	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Saos-2	Mk\1dWhVWyCjc4PhfS=>				NI[1UXByUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU3Hvd{0zKGOnbHzz	MmLQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
OHS-50	MV;xTHRUKGG\|c3H5				NVG2NoIyeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF;IV{02OCClZXzsdy=>	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh41	NF7H[oZyUFSVIHHzd4F6				NVOxPItyeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLoOFEh[2WubIO=	M1nzd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-RPS6 / T-RPS6 / p-4E-BP1 / T-4E-BP1; PubMed: 23535559 Leukemia Four AML cell lines (a and b) were treated for 24 hours with vehicle versus R406. Western blots of (a) p-RPS6 (Ser240/244) and (b) p-4E-BP1 (Thr37/46). p-MEK / T-MEK / p-ERK / T-ERK; PubMed: 23535559 Leukemia AML cell lines were treated with vehicle versus R406. Western blots of p-MEK1/2 (Ser217/221) and p-ERK1/2 (Thr202/Tyr204) are depicted. p-c-RAF / T-c-RAF; PubMed: 23535559 Leukemia Effect of SYK inhibition on c-RAF in AML cells. AML cells were grown in the presence of 4 μM R406 for the indicated times and assessed for activation of c-RAF and ERK1/2. p-AKT / T-AKT / p-mTOR / T-mTOR; PubMed: 23535559 Leukemia Western blot of (a) p-AKT (Ser473) or (b) p-mTOR (Ser2448) in AML cell lines treated with R406 for 24 hours.	23535559
Growth inhibition assay	Cell viability (U87, U251 cells); PubMed: 31043589 Cell Death Dis U87 and U251 were insensitive to R406, with a calculated IC50 of more than 1 mM for both cell lines. Cell viability (GSC lines); PubMed: 31043589 Cell Death Dis Incubation with R406 significantly reduced the cell viability of both GSC lines, with an IC50 of 0.75 μM for GSC-1 and 0.89 μM for GSC-2 respectively.	31043589

体内研究

在已经预防处理的鼠内进行阳性Arthus 反应，5 mg/kg R406诱导鼠皮肤病变达到86%。R406作用于抗体诱导的关节炎鼠模型，也有效抑制炎症。^[1] 自身免疫反应时，R406不会影响巨噬细胞和嗜中性粒细胞的功能，免疫毒性为最低水平。^[3]

动物实验：^[1]	- 合并 Animal Models: 在C57BL/6鼠中腹腔注射150 μL 取自成年K/BxN鼠的混合血清诱导产生关节炎。 Dosages: 1 或5 mg/kg Administration: 口服处理 (Only for Reference)

参考文献

[4] Zhu Y, et al. Toxicol Appl Pharmacol, 2007, 221(3), 268-277.

- 合并

溶解度 (25°C)

体外	DMSO	100 mg/mL (159.07 mM)
	Water	Insoluble
	Ethanol	0 mg/mL (0.0 mM)
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5%dmso+95%cornoil	6mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download R406 SDF

分子量	628.63
化学式	C₂₂H₂₃FN₆O₅.C₆H₆O₃S
CAS号	841290-81-1
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01725230	Completed	Drug: Fostamatinib\|Drug: Rosuvastatin\|Drug: Simvastatin	Rheumatoid Arthritis	AstraZeneca	November 2012	Phase 1
NCT01598571	Completed	Drug: Fostamatinib	Healthy	AstraZeneca	May 2012	Phase 1
NCT01387308	Completed	Drug: Fostamatinib	Healthy	AstraZeneca	August 2011	Phase 1
NCT01355354	Completed	Drug: Digoxin\|Drug: Fostamatinib	Healthy Volunteers\|Rheumatoid Arthritis	AstraZeneca	June 2011	Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
What’s the difference between S1533 and S2194?
回答：
S1533 and S2194 are two different forms of R406. S1533 is the free base form, containing only R406 molecule without a acid added to it. S2194 has an additional C6H6O3S acid on it which makes the molecule a salt form. The free base and salt forms have same biology activities. Free base has a lower molecular weight and salt form has a better solubility in DMSO.

Syk Signaling Pathway Map

Syk Inhibitors with Unique Features

活性最高的Syk抑制剂

PRT062607 (P505-15, BIIB057) HCl : Syk, IC50=1 nM.
用于临床的Syk抑制剂

Fostamatinib (R788) : Phase III for Rheumatoid Arthritis.
最新的Syk抑制剂

PRT062607 (P505-15, BIIB057) HCl : Novel, highly selective Syk inhibitor with IC50 of 1 nM, >80-fold selective for Syk than Fgr, Lyn, FAK, Pyk2 and Zap70.
经典的Syk抑制剂

R406 (free base) : Syk inhibitor with IC50 of 41 nM, strongly inhibits Syk but not Lyn, 5-fold less potent to Flt3. Phase 2.

研究领域

产品类型

定制您的化合物库

R406

客户使用Selleck生产的R406发表文献64篇：

产品安全说明书

Syk抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download R406 SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-01-06)

技术支持

常见问题及建议解决方法

Syk Signaling Pathway Map

Syk Inhibitors with Unique Features

相关Syk产品